文献速递肺结节与肺癌

Glecirasib联合Sitneprotafib治疗中国KRASG12C突变NSCLC的1/2a期试验

Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial.
PubMed 文献 · Lancet Respir Med · 2025-11-29

这项开放标签、多中心、单臂1/2a期试验评估了KRASG12C抑制剂Glecirasib联合SHP2抑制剂Sitneprotafib在KRASG12C突变实体瘤患者中的安全性和疗效。共入组194例患者,其中171例为NSCLC。在初治NSCLC患者中客观缓解率(ORR)达71%,既往接受过KRASG12C抑制剂治疗者ORR为10%。联合方案安全性可控,支持开展3期试验。

要点

  • 初治KRASG12C突变NSCLC患者ORR达71%(95%CI 61-79)。
  • 既往KRASG12C抑制剂经治患者ORR仅10%(95%CI 2-27)。
  • 最常见治疗相关不良事件为贫血(61%)和高甘油三酯血症(60%)。

核心结论

  • Glecirasib联合Sitneprotafib在晚期KRASG12C突变NSCLC中显示出有前景的疗效和可控的安全性,尤其在未接受过治疗的患者中。

研究设计与样本

  • 开放标签、多中心、单臂1/2a期试验,在中国26家医院开展。
  • 入组194例KRASG12C突变晚期实体瘤患者,其中171例(88%)为NSCLC。
  • 患者接受口服Glecirasib(400 mg或800 mg每日一次)联合口服Sitneprotafib(2 mg或3 mg每日一次),共7个队列评估不同剂量和方案。
  • 1期主要终点为安全性,2a期主要终点为客观缓解率(ORR)。

主要发现

  • 1期最高剂量组(Glecirasib 800 mg联合Sitneprotafib 3 mg每日一次,用1周停1周)出现1例剂量限制性毒性(3级肺炎),其他剂量组未观察到DLTs。
  • 167例(98%)患者发生至少1例治疗相关不良事件,78例(46%)为3-4级。
  • 最常见治疗相关不良事件(≥20%)包括贫血(105例[61%])、高甘油三酯血症(103例[60%])、天冬氨酸氨基转移酶升高(95例[56%])、丙氨酸氨基转移酶升高(83例[49%])、血胆红素升高(78例[46%])、水肿(62例[36%])、血肌酸磷酸激酶升高(60例[35%])、中性粒细胞减少(54例[32%])、白细胞计数降低(50例[29%])和体重增加(44例[26%])。
  • 3例(2%)患者因治疗相关不良事件终止Glecirasib和Sitneprotafib,未报告5级治疗相关不良事件。

关键数值与推荐

  • 初治NSCLC患者ORR 71%(95%CI 61-79)。
  • 既往系统治疗但KRASG12C抑制剂初治患者ORR 49%(95%CI 32-65)。
  • 既往KRASG12C抑制剂经治患者ORR 10%(95%CI 2-27)。

临床怎么用

  • 对于未接受过治疗的KRASG12C突变晚期NSCLC患者,Glecirasib联合Sitneprotafib提供了高缓解率的无化疗选择。
  • 治疗期间需重点监测贫血、高甘油三酯血症、肝酶升高和肺炎等不良事件。
  • 既往KRASG12C抑制剂经治患者从该联合方案中获益有限,需考虑其他策略。

局限性

  • 单臂设计,无对照组,无法直接比较联合方案与标准治疗。
  • 样本量有限,部分亚组(如经治患者)例数较少。
  • 随访时间尚短,无进展生存期和总生存期数据未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Monotherapy with KRASG12C (ie, KRAS Gly12Cys) inhibitors has emerged as a mainstream treatment for patients with KRASG12C -mutated non-small-cell lung cancer (NSCLC). Synergistic effects have been observed with the combination of a KRASG12C inhibitor and a SHP2 inhibitor in multiple xenograft models. We aimed to evaluate the safety and efficacy of the KRASG12C inhibitor glecirasib combined with the SHP2 inhibitor sitneprotafib (JAB-3312; Jacobio Pharmaceuticals, Beijing, China) in patients with KRASG12C -mutated solid tumours. METHODS: We conducted an open-label, multicentre, single-arm, phase 1/2a trial at 26 hospitals across China. Patients (aged ≥18 years) with locally advanced or metastatic solid tumours harbouring a KRASG12C mutation, an Eastern Cooperative Oncology Group performance status score of 0-1, and measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST; version 1.1) were eligible for inclusion in both phases. Patients received oral glecirasib (400 mg or 800 mg once daily) in combination with oral sitneprotafib (2 mg or 3 mg once daily) in seven cohorts evaluating various dose levels and schedules of the two drugs. In phase 1, the primary endpoint was safety assessed by investigators according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0) from first treatment dose to 30 days after the last dose of both agents. In phase 2a, the primary endpoint was objective response rate (ORR) between baseline and disease progression or initiation of anticancer therapy, whichever occurred first, based on the comprehensive assessment of all tumour evaluations by investigators following RECIST (version 1.1). All patients who received at least one dose of combination therapy were included in the safety and efficacy analyses. This trial is registered with ClinicalTrials.gov (NCT05288205) and is currently recruiting. FINDINGS: Between May 7, 2022, and Aug 20, 2024, a total of 194 patients with advanced solid tumours were enrolled, of whom 171 (88%) had NSCLC (50 [29%] in phase 1 and 121 [71%] in phase 2a). Median participant age was 65 years (IQR 59-70); 140 (82%) were men and 31 (18%) were women. At data cutoff on Aug 20, 2024, the median follow-up duration was 14·5 months (IQR 11·9-17·1), and 106 (62%) patients had discontinued treatment. Phase 1 concluded with one dose-limiting toxicity (DLT; grade 3 pneumonitis) at the highest dose level (glecirasib 800 mg plus sitneprotafib 3 mg once daily, 1 week on and 1 week off); no DLTs were observed at other dose levels. Across phase 1 and 2a, 167 patients (98%) had at least one treatment-related adverse event, which were grade 3-4 in 78 (46%) patients. The most common treatment-related adverse events (occurring in ≥20% of all 171 patients) were anaemia (105 [61%]), hypertriglyceridaemia (103 [60%]), increased aspartate aminotransferase (95 [56%]), increased alanine aminotransferase (83 [49%]), increased blood bilirubin (78 [46%]), oedema (62 [36%]), increased blood creatine phosphokinase (60 [35%]), neutropenia (54 [32%]), decreased white blood cell count (50 [29%]), and increased bodyweight (44 [26%]). Three (2%) patients discontinued glecirasib and sitneprotafib due to treatment-related adverse events. No grade 5 treatment-related adverse event was reported. The ORR was 71% (72 patients [95% CI 61-79]) in the subgroup of 102 patients with previously untreated NSCLC; 49% (19 patients [32-65]) in the 39 patients previously treated with systemic therapy but naive to KRASG12C inhibitors; and 10% (three patients [2-27]) in the 30 patients previously treated with KRASG12C inhibitor therapy. INTERPRETATION: Glecirasib combined with sitneprotafib showed promising efficacy and manageable safety in patients with advanced KRASG12C -mutated NSCLC, particularly among those who had not received previous treatment. These findings support the evaluation of this combination in a phase 3 trial comparing this chemotherapy-free regimen to current standard of care in this patient group. FUNDING: Jacobio Pharmaceuticals. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Zhong J, Zhao J, Duan J, et al. Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial. Lancet Respir Med. 2025. PMID: 41325755. doi:10.1016/S2213-2600(25)00258-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。